HHS report defends ACA deductibles as reasonable

A new analysis from HHS argued against the perception that deductibles and out-of-pocket costs for insurance plans offered on Affordable Care Act exchanges are too high.

HHS said the median deductible for an individual covered by a marketplace plan is $850, down from $900 in 2015.

Other studies have given much higher figures, such as a November 2015 analysis from the Kaiser Foundation that placed the average deductible for a mid-level plan at $3,064. The difference, according to HHS, is other studies don’t take into account financial subsidies available under the ACA.

“As with marketplace premiums, many consumers’ deductibles are well below the deductible that would apply without financial assistance, so ignoring financial assistance gives a misleading picture of what consumers actually pay,” HHS said.

While HHS emphasizes the median figure, the same analysis also shows 43 percent of enrollees on the marketplace have an average deductible of $2,500 or more.

The analysis also emphasizes what services marketplace plans cover before meeting the deductible. HHS said those policies cover an average of seven services completely or with a co-pay, like generic drugs or primary care visits.

“This means that even though a health plan has a deductible, it might not matter for the services used most frequently, like primary care visits or prescription drugs,” HHS said. “In other words, just looking at the deductibleeven after accounting for cost-sharing reductionsdoes not provide an accurate picture of marketplace consumers’ access to care.”

HHS added that a third of marketplace customers are enrolled in a plan that covers 10 or more services before the deductible. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.